Video Reports

Jeffrey S. Weber, MD, PhD: OK, so let me ask you this, if we can switch gears a very small amount. We all agree the adjuvant therapy has really changed how we treat our melanoma patients or the availability of adjuvant BRAF/MEK, dabrafenib-trametinib, nivolumab, pembrolizumab.

Jeffrey S. Weber, MD, PhD: And there was actually a compilation done, meaning a whole series of studies, and I think that’s an oral presentation.

Source: OncLive, August 2019 Transcript: Jeffrey S. Weber, MD, PhD: You’ve seen the patient. The testing is in. How do the data from recent trials influence your management in the adjuvant…

Source: Targeted Oncology, July 2019 Nikhil I. Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center, discusses the rationale for combining nivolumab (Opdivo) with bempegaldesleukin (NKTR-214) for the…